查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574948

CRBSI 治療市場，按藥物類別、按給藥途徑、按適應症、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

CRBSI Treatment Market, By Drug Class, By Route of Administration, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023 年 CRBSI 治療市場規模為 15.3032 億美元，2024 年至 2032 年複合年成長率為 5.20%。

CRBSI 處理市場-市場動態

導管相關感染的流行增加了對有效治療的需求。

導管相關血流感染 (CRBSI) 盛行率的上升是 CRBSI 治療市場的重要驅動力。患者和醫療保健提供者對 CRBSI 相關風險的認知不斷提高，導致人們更加重視預防策略。隨著醫療保健行業優先考慮患者安全並努力減少院內感染，對 CRBSI 治療的需求持續成長，使其成為醫療保健市場研發的關鍵領域。

根據美國疾病管制與預防中心 (CDC) 的數據，美國每年發生約 25 萬例血流感染病例，其中許多與中心靜脈導管有關。這凸顯了迫切需要有效的治療和預防措施。醫療機構擴大採用先進的感染控制方案，例如抗菌導管，並加強對醫護人員的導管護理培訓。

CRBSI 治療市場 - 主要見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 5.20% 左右的複合年成長率成長

根據藥物類別細分，預計萬古黴素將在 2023 年顯示最大市場佔有率

根據跡象，細菌感染是 2023 年的主要類型

根據給藥途徑細分，注射劑是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

CRBSI 治療市場-細分分析：

全球 CRBSI 治療市場根據藥物類別、給藥途徑、適應症和地區進行細分。

市面上依藥物類別分為七類：氯唑西林、頭孢他啶、頭孢唑啉、達托黴素、萬古黴素、替考拉寧、棘白菌素等。萬古黴素是 CRBSI 治療市場中最主要的部分。這種抗生素對經常引起這些感染的抗甲氧西林金黃色葡萄球菌 (MRSA) 效果很好。醫療保健提供者喜歡它，因為它對多種類型的細菌可靠且有效。萬古黴素使用歷史悠久，安全記錄良好，更值得信賴。隨著抗生素抗藥性的增加，對萬古黴素等有效治療方法的需求仍然很高。總體而言，其有效性和醫療專業人士的信任使其在 CRBSI 治療中名列前茅。

根據適應症，市場分為三類：細菌感染、真菌感染、病毒和寄生蟲感染以及其他。細菌感染是 CRBSI（導管相關血流感染）治療市場的最大部分。細菌是這些感染最常見的原因，可能導致嚴重的健康問題。治療通常涉及抗生素，它對多種細菌有效。留置導管患者的大量細菌感染增加了對這些治療的需求。此外，醫療保健提供者專注於減少細菌感染併發症的快速解決方案，這有助於這部分市場的進一步成長。

CRBSI 處理市場 - 地理洞察

北美導管相關血流感染（CRBSI）治療市場正在快速成長。這一成長主要是因為越來越多的人入院並使用中心靜脈導管。醫院正致力於更好地控制感染，增加對有效治療的需求。政府對感染控制計畫的支持也是該市場的重要驅動力。更嚴格的醫療保健法規鼓勵醫院採用改進的做法和產品。因此，患者正在接受更安全、更有效的照護。

CRBSI 處理市場-競爭格局：

導管相關血流感染 (CRBSI) 市場競爭激烈，包括 Bard Medical (BD)、Medtronic 和 Teleflex 等重要公司。巴德醫療以其創新的導管設計而聞名。美敦力（Medtronic）在世界各地提供廣泛的產品。泰利福透過先進的設計來預防感染，並注重病人安全。

Smith's Medical 專注於血管通路，並高度重視品質和安全性。 Fresenius Kabi 以其重症監護產品而聞名，AngioDynamics 則專注於微創手術。 B. Braun Melsungen AG 提供各種醫療設備並重視永續性。這些公司努力創造新的解決方案並改善感染預防，使市場活躍且充滿活力。

最新進展：

2023 年 8 月，Citius Pharmaceuticals, Inc. 宣布了 Mino-Lok 臨床試驗的一個重要里程碑，Mino-Lok 是一種抗生素封管溶液，旨在保存導管相關血流感染患者的導管。該公司報告稱，完成試驗所需的 92 項任務都已完成。一些患者仍在接受治療，這可能會導致其他事件。

2023 年 7 月，Teva Pharmaceuticals, Inc. 和 Alvotech 透露，他們打算加強現有的策略合作夥伴關係，旨在開發和推出多種生物相似藥候選藥物。作為此次合作的一部分，Teva 將透過購買 Alvotech 發行的次級可轉換債券來額外投資 4,000 萬美元。

目錄

第1章：CRBSI 治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的 CRBSI 治療市場片段
    • CRBSI 治療市場片段（依給藥途徑）
    • CRBSI 治療市場片段（按適應症）
    • CRBSI 治療市場片段（按國家/地區）
    • 按地區分類的 CRBSI 治療市場片段
  • 競爭洞察

第 3 章：CRBSI 主要市場趨勢

  • CRBSI 治療市場促進因素
    • 市場促進因素的影響分析
  • CRBSI 治療市場限制
    • 市場限制影響分析
  • CRBSI 處理市場機會
  • CRBSI 治療市場未來趨勢

第 4 章：CRBSI 產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：CRBSI 治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：CRBSI 處理市場格局

  • CRBSI 治療市場佔有率分析，2023 年
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：CRBSI 治療市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 鄰氯西林
    • 頭孢他啶
    • 頭孢唑啉
    • 達托黴素
    • 萬古黴素
    • 替考拉寧
    • 棘白菌素
    • 其他

第 8 章：CRBSI 治療市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 可注射

第 9 章：CRBSI 治療市場 - 按適應症分類

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 細菌感染
    • 黴菌感染
    • 病毒和寄生蟲感染
    • 其他

第 10 章：CRBSI 治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • CRBSI 北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按指標）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • CRBSI 歐洲主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模與預測（按指標）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • CRBSI 亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模與預測（依指標）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • CRBSI 拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按指標）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • CRBSI 中東和非洲主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（依指標）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - CRBSI 產業

  • 競爭儀表板
  • 公司簡介
    • Bard Medical
    • Medtronic
    • Teleflex
    • Smith's Medical
    • Halyard Health
    • Fresenius Kabi
    • AngioDynamics
    • Vygon
    • B. Braun Melsungen AG
    • Nipro Corporation
    • Cook Medical
    • Amsino International
    • Merit Medical Systems
    • Pall Corporation
    • CR Bard
    • Ruhof Healthcare
    • Inspire Medical Systems
    • Abbott Laboratories

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3951

REPORT HIGHLIGHT

CRBSI Treatment Market size was valued at USD 1,530.32 Million in 2023, expanding at a CAGR of 5.20% from 2024 to 2032.

CRBSI stands for Catheter-Related Bloodstream Infections. It happens when bacteria enter the bloodstream through a catheter, a tube used for medical treatments. The treatment market for CRBSI includes various products and therapies designed to prevent and manage these infections. This market offers antibiotics, antiseptics, and advanced catheter designs that reduce infection risk. Hospitals and healthcare providers invest in these solutions to improve patient safety and outcomes. The goal is to minimize infections, which can lead to serious health issues and longer hospital stays.

CRBSI Treatment Market- Market Dynamics

The prevalence of catheter-related infections boosts demand for effective treatments.

The rising prevalence of catheter-related bloodstream infections (CRBSI) is a significant driver for the CRBSI treatment market. Growing awareness among patients and healthcare providers about the risks associated with CRBSIs is leading to a greater emphasis on prevention strategies. As the healthcare sector prioritizes patient safety and strives to reduce hospital-acquired infections, the demand for CRBSI treatments continues to grow, making it a crucial area for research and development in the healthcare market.

According to the Centers for Disease Control and Prevention (CDC), about 250,000 cases of bloodstream infections occur in the U.S. each year, with many linked to central line catheters. This highlights the urgent need for effective treatments and preventive measures. Healthcare institutions are increasingly adopting advanced infection control protocols, such as antimicrobial-impregnated catheters, and enhanced training for healthcare staff on catheter care.

CRBSI Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.20% over the forecast period (2024-2032)

Based on Drug Class segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication, Bacterial Infections was the leading type in 2023

Based on Route of Administration segmentation, Injectable was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

CRBSI Treatment Market- Segmentation Analysis:

The Global CRBSI Treatment Market is segmented based on Drug Class, Route of Administration, Indication, and Region.

The market is divided into Seven categories based on Drug Class: Cloxacillin, Ceftazidime, Cefazoline, Daptomycin, Vancomycin, Teicoplanin, Echinocandin, and Others. Vancomycin is the most dominant segment in the CRBSI treatment market. This antibiotic works well against methicillin-resistant Staphylococcus aureus (MRSA), which often causes these infections. Healthcare providers like it because it is reliable and effective against many types of bacteria. Vancomycin has been used for a long time and has a strong safety record, making it even more trusted. As antibiotic resistance increases, the need for effective treatments like Vancomycin is still high. Overall, its effectiveness and the trust of medical professionals keep it at the top of CRBSI treatment.

The market is divided into three categories based on the Indication: Bacterial Infections, Fungal Infections, Viral and Parasitic Infections, and Others. Bacterial infections are the biggest part of the CRBSI (Catheter-Related Bloodstream Infection) treatment market. bacteria are the most common cause of these infections and can lead to serious health problems. Treatments usually involve antibiotics, which are effective against many types of bacteria. The high number of bacterial infections in patients with catheters increases the demand for these treatments. Also, healthcare providers focus on quick solutions to reduce complications from bacterial infections, which helps this part of the market grow even more.

CRBSI Treatment Market- Geographical Insights

North America's catheter-related bloodstream infection (CRBSI) treatment market is growing quickly. This growth is mainly because more people are admitted to hospitals and using central venous catheters. Hospitals are focusing on better infection control, increasing the demand for effective treatments. Government support for infection control programs is also an important driver for this market. Stricter healthcare regulations encourage hospitals to adopt improved practices and products. As a result, patients are receiving safer and more effective care.

CRBSI Treatment Market- Competitive Landscape:

The catheter-related bloodstream infections (CRBSI) market is competitive and includes important companies like Bard Medical (BD), Medtronic, and Teleflex. Bard Medical is known for its innovative catheter designs. Medtronic offers a wide range of products around the world. Teleflex focuses on patient safety with advanced designs to prevent infections.

Smith's Medical specializes in vascular access and puts a strong emphasis on quality and safety. Fresenius Kabi is well-known for its critical care products, and AngioDynamics focuses on minimally invasive procedures. B. Braun Melsungen AG offers a variety of medical devices and values sustainability. These companies work hard to create new solutions and improve infection prevention, making the market active and dynamic.

Recent Developments:

In August 2023, Citius Pharmaceuticals, Inc. announced a significant milestone for the clinical trial of Mino-Lok, an antibiotic lock solution designed to preserve catheters in patients with catheter-related bloodstream infections. The company reported that all 92 required events to complete the trial have been achieved. Some patients are still undergoing treatment, which may result in additional events.

In July 2023, Teva Pharmaceuticals, Inc. and Alvotech revealed their intention to strengthen their existing strategic partnership aimed at developing and launching several biosimilar candidates. As part of this collaboration, Teva will invest an additional US$ 40 million by purchasing subordinated convertible bonds to be issued by Alvotech.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRBSI TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bard Medical
  • Medtronic
  • Teleflex
  • Smith's Medical
  • Halyard Health
  • Fresenius Kabi
  • AngioDynamics
  • Vygon
  • B. Braun Melsungen AG
  • Nipro Corporation
  • Cook Medical
  • Amsino International
  • Merit Medical Systems
  • Pall Corporation
  • C.R. Bard
  • Ruhof Healthcare
  • Inspire Medical Systems
  • Abbott Laboratories

GLOBAL CRBSI TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cloxacillin
  • Ceftazidime
  • Cefazoline
  • Daptomycin
  • Vancomycin
  • Teicoplanin
  • Echinocandin
  • Others

GLOBAL CRBSI TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable

GLOBAL CRBSI TREATMENT MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Bacterial Infections
  • Fungal Infection
  • Viral and Parasitic Infections
  • Others

GLOBAL CRBSI TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CRBSI Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CRBSI Treatment Market Snippet by Drug Class
    • 2.1.2. CRBSI Treatment Market Snippet by Route of Administration
    • 2.1.3. CRBSI Treatment Market Snippet by Indication
    • 2.1.4. CRBSI Treatment Market Snippet by Country
    • 2.1.5. CRBSI Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. CRBSI Key Market Trends

  • 3.1. CRBSI Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CRBSI Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CRBSI Treatment Market Opportunities
  • 3.4. CRBSI Treatment Market Future Trends

4. CRBSI Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CRBSI Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. CRBSI Treatment Market Landscape

  • 6.1. CRBSI Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CRBSI Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Cloxacillin
    • 7.1.3. Ceftazidime
    • 7.1.4. Cefazoline
    • 7.1.5. Daptomycin
    • 7.1.6. Vancomycin
    • 7.1.7. Teicoplanin
    • 7.1.8. Echinocandin
    • 7.1.9. Others

8. CRBSI Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable

9. CRBSI Treatment Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Bacterial Infections
    • 9.1.3. Fungal Infection
    • 9.1.4. Viral and Parasitic Infections
    • 9.1.5. Others

10. CRBSI Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. CRBSI Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. CRBSI Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. CRBSI Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. CRBSI Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. CRBSI Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- CRBSI Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Bard Medical
    • 11.2.2. Medtronic
    • 11.2.3. Teleflex
    • 11.2.4. Smith's Medical
    • 11.2.5. Halyard Health
    • 11.2.6. Fresenius Kabi
    • 11.2.7. AngioDynamics
    • 11.2.8. Vygon
    • 11.2.9. B. Braun Melsungen AG
    • 11.2.10. Nipro Corporation
    • 11.2.11. Cook Medical
    • 11.2.12. Amsino International
    • 11.2.13. Merit Medical Systems
    • 11.2.14. Pall Corporation
    • 11.2.15. C.R. Bard
    • 11.2.16. Ruhof Healthcare
    • 11.2.17. Inspire Medical Systems
    • 11.2.18. Abbott Laboratories

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us